Letter/Communication
Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
The New England journal of medicine, Vol.394(11), pp.1139-1140
03/12/2026
DOI: 10.1056/NEJMc2600540
PMID: 41812204
Abstract
To the Editor: The results of the VALIANT trial reported by Fakhouri et al. (Dec. 4 issue)1 provide compelling evidence that proximal C3 inhibition with pegcetacoplan can substantially reduce the degree of proteinuria and stabilize kidney function in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN). These results represent a major therapeutic advance for patients with disorders historically associated with poor renal prognosis and limited treatment options.2-5 Beyond its therapeutic implications, the trial reinforces the indispensable role of kidney biopsy in establishing a definitive diagnosis. In contemporary pediatric practice, genetic testing is increasingly being performed before biopsy; however, . . .
Details
- Title: Subtitle
- Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
- Creators
- Sevcan A. Bakkaloglu - Gazi UniversityEmre Leventoglu - Konya City Hosp, Konya, TurkiyeFadi Fakhouri - University of LausanneCarla M. Nester - University of Iowa
- Resource Type
- Letter/Communication
- Publication Details
- The New England journal of medicine, Vol.394(11), pp.1139-1140
- DOI
- 10.1056/NEJMc2600540
- PMID
- 41812204
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Soc
- Number of pages
- 2
- Language
- English
- Date published
- 03/12/2026
- Academic Unit
- Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Internal Medicine
- Record Identifier
- 9985147183002771
Metrics
1 Record Views